MARKET

MYOV

MYOV

MYOVANT SCIENCES
NYSE

Real-time Quotes | Nasdaq Last Sale

23.85
+1.39
+6.19%
Closed 18:14 03/01 EST
OPEN
22.55
PREV CLOSE
22.46
HIGH
24.07
LOW
22.55
VOLUME
643.40K
TURNOVER
--
52 WEEK HIGH
30.90
52 WEEK LOW
5.98
MARKET CAP
2.17B
P/E (TTM)
-8.9547
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
GnRH Receptor Antagonists Market Growth Analysis, Trends Forecast Regions, Type and Application to 2020 -2027 By Ameco Research
Comserve · 4d ago
Gonadotropin-releasing Hormone Antagonists Market Global Market Size, Share, Development, Growth and Demand Forecast, 2020-2027 By Ameco Research
Comserve · 4d ago
Prostate Cancer Pipeline, Clinical Trials and Emerging Therapy Assessment by DelveInsight
Feb 25, 2021 (AB Digital via COMTEX) -- DelveInsight has launched a new report on Prostate Cancer Pipeline   Prostate cancer is a type of malignancy...
ABNewswire · 4d ago
Heavy Menstrual Bleeding (HMB)- Market Insights, Epidemiology and Market Forecast--2028
Feb 25, 2021 (Heraldkeepers) -- DelveInsight's 'Heavy Menstrual Bleeding (HMB)- Market Insights, Epidemiology and Market Forecast--2028' report delivers an...
Heraldkeepers · 4d ago
Pharmaceuticals for Women’s Health: Global Markets
Heraldkeepers · 4d ago
The impact of COVID-19 on Endometriosis Treatment Drugs Market Growth, Trends, Industry Outlook, Growth Opportunity, Business Growth And Forecast (2021 - 2026)
Feb 25, 2021 (The Expresswire) -- The Endometriosis Treatment Drugs industry has undergone many changes in recent years and expects numerous variations in...
The Express Wire · 5d ago
Endometriosis Market Size, Share Global Trend, Industry News, Industry Demand, Business Growth, Top Key Players Update, Business Statistics and Research Methodology by Forecast to 2025
Feb 23, 2021 (The Expresswire) -- Global Endometriosis Market Research report discusses the market growth drivers and challenges that the manufacturer and...
The Express Wire · 02/23 06:18
Global Uterine Fibroid Treatment Market 2020 Business Outlook with COVID-19 Scenario to 2025
CDN Newswire · 02/22 18:45
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MYOV. Analyze the recent business situations of MYOVANT SCIENCES through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MYOV stock price target is 35.86 with a high estimate of 55.00 and a low estimate of 26.00.
EPS
Institutional Holdings
Institutions: 163
Institutional Holdings: 44.61M
% Owned: 49.13%
Shares Outstanding: 90.80M
TypeInstitutionsShares
Increased
31
4.10M
New
45
-1.17M
Decreased
31
2.85M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.13%
Pharmaceuticals & Medical Research
+1.38%
Key Executives
Chairman/Director
Myrtle Potter
Chief Executive Officer/Director
David Marek
Chief Financial Officer/Chief Accounting Officer
Frank Karbe
General Counsel/Secretary
Matthew Lang
Other/Director
Adele Gulfo
Other
Juan Camilo Arjona Ferreira
Lead Director/Independent Director
Kathleen Sebelius
Other
Kim Sablich
Director
Hiroshi Nomura
Independent Director
Terrie Curran
Independent Director
Mark Guinan
  • Dividends
  • Splits
  • Insider Activity
No Data
About MYOV
Myovant Sciences Ltd, is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment women’s health and endocrine diseases. Its lead product candidate is Relugolix, which is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland. Inhibition of GnRH receptors decreases the release of the gonadotropins, luteinizing hormone (LH), and follicle-stimulating hormone (FSH), thereby decreasing the down-stream production of estrogen and progesterone by the ovaries in women and testosterone by the testes in men. It is also advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. The Company is developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility.

Webull offers kinds of Myovant Sciences Ltd stock information, including NYSE:MYOV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MYOV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MYOV stock methods without spending real money on the virtual paper trading platform.